{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:55Z","timestamp":1790821555359,"version":"4.1.0"},"reference-count":15,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cryptogenic organizing pneumonia (COP) is an interstitial lung disease, with causes including anti-CD20 antibodies. Ocrelizumab is a humanized monoclonal antibody against CD20 approved for use in relapsing-remitting or primary progressive multiple sclerosis (MS), with no conclusive data regarding pulmonary toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Cases:<\/jats:title>\n                    <jats:p>We describe two cases of COP associated with ocrelizumab use in multiple sclerosis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>We suggest considering COP whenever respiratory symptoms arise in MS patients receiving ocrelizumab therapy. COP diagnosis requires clinical and radiological exclusion of alternative diagnoses such as opportunistic infections, autoimmunity, drugs, and neoplasms. Appropriate steroid therapy has an excellent clinical response rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13524585241295677","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T05:18:13Z","timestamp":1732166293000},"page":"740-743","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review"],"prefix":"10.1177","volume":"31","author":[{"given":"Alessandro","family":"Gans","sequence":"first","affiliation":[{"name":"Neurology and Stroke Unit, Department of Neuroscience, Legnano Hospital, ASST Ovest Milanese, Legnano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Pinuccia","family":"Verrengia","sequence":"additional","affiliation":[{"name":"Neurology and Stroke Unit, Department of Neuroscience, Legnano Hospital, ASST Ovest Milanese, Legnano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Ricchiuti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Legnano Hospital, ASST Ovest Milanese, Legnano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Leva","sequence":"additional","affiliation":[{"name":"Neurology and Stroke Unit, Department of Neuroscience, Legnano Hospital, ASST Ovest Milanese, Legnano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Brajkovic","sequence":"additional","affiliation":[{"name":"Neurology and Stroke Unit, Department of Neuroscience, Legnano Hospital, ASST Ovest Milanese, Legnano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Colombo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Legnano Hospital, ASST Ovest Milanese, Legnano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Mazzone","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Legnano Hospital, ASST Ovest Milanese, Legnano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Prelle","sequence":"additional","affiliation":[{"name":"Neurology and Stroke Unit, Department of Neuroscience, Legnano Hospital, ASST Ovest Milanese, Legnano, MI, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.044"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517751049"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01672-9"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2005.05.007"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.5578\/tt.20239913"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diii.2014.01.004"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.10.009"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080209"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500144615"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/hon.799"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2007.39.2.88"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.1390295"},{"issue":"3","key":"e_1_3_2_14_2","first-page":"602","article-title":"Rituximab-related cryptogenic organizing pneumonia and late onset neutropenia in a patient with non-Hodgkin lymphoma: Report of two rare complications and review of the literature","volume":"17","author":"Urun Y","year":"2012","unstructured":"Urun Y, Dincol D, Kumbasar OO. Rituximab-related cryptogenic organizing pneumonia and late onset neutropenia in a patient with non-Hodgkin lymphoma: Report of two rare complications and review of the literature. J BUON 2012; 17(3): 602\u2013603.","journal-title":"J BUON"},{"key":"e_1_3_2_15_2","article-title":"Rituximab-induced immune dysregulation leading to organizing pneumonia, bronchiectasis, and pulmonary fibrosis","volume":"15","author":"Ayyad M","year":"2023","unstructured":"Ayyad M, Azar J, Albandak M, et al. Rituximab-induced immune dysregulation leading to organizing pneumonia, bronchiectasis, and pulmonary fibrosis. Cureus 2023; 15: e34798.","journal-title":"Cureus"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.12.659"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585241295677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585241295677","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585241295677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:16:47Z","timestamp":1777695407000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585241295677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/13524585241295677"],"URL":"https:\/\/doi.org\/10.1177\/13524585241295677","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}